| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcbaca38a267d92985f97e6f4b631c61 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0459
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06 |
| filingDate |
2011-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7db3b4dac077fff34932c552b68a6c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1800afac7d6111a7ae35bfec113f3201
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc25cc7e7f0356f0742af0679f84c0b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63d7341e47215a20cfb6eb58b827b572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7451516322fd126ac58eb27797ef2715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9584650cbb581f98cb9a6032be0e1846 |
| publicationDate |
2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2816037-A2 |
| titleOfInvention |
New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof |
| abstract |
The invention relates to a new class of compounds able to inhibit with high affinity and selectivity the 5-HT7 receptor. The invention also relates to the utilization of such compounds as medicaments useful in the treatment and prevention of 5-HT7 receptor relating disorders of the central nervous system. The invention also relates to the isotopically labeled compounds for use in vivo diagnosis or imaging of a 5-HT7 condition. |
| priorityDate |
2011-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |